Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Claire N Harrison, Alessandro Maria Vannucchi, Christian Recher, Francesco Passamonti, Aaron T. Gerds, Juan Carlos Hernandez Boluda, Abdulraheem Yacoub, Shireen Sirhan, Jun Kawashima, Bharat Patel, Bryan Strouse, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2023-178816

Published: 2023

Journal Articles

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Vikas Gupta, Claire N Harrison, Boris Gorsh, Bharat Patel, Zhaohui Wang, Molly Purser, Catherine Ellis, Bryan Strouse, Dwaipayan Patnaik, Jun Kawashima, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2023-178772

Published: 2023

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Blood (2022) 140 (Supplement 1): 6803–6805.

https://doi.org/10.1182/blood-2022-162877

Published: 2022

Journal Articles

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Blood (2022) 140 (Supplement 1): 821–823.

https://doi.org/10.1182/blood-2022-160409

Published: 2022

Journal Articles

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Jean-Jacques Kiladjian, Stephen T Oh, Timothy Devos, Francesco Passamonti, Miklos Egyed, Alessandro Vannucchi, Andrzej Pluta, Donal P McLornan, Jun Kawashima, Mei Huang, Bryan Strouse, Claire Harrison

Blood (2022) 140 (Supplement 1): 3983–3985.

https://doi.org/10.1182/blood-2022-159636

Published: 2022

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

Journal Articles

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Blood (2022) 140 (Supplement 1): 9670–9672.

https://doi.org/10.1182/blood-2022-162543

Published: 2022

Journal Articles

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Sattva S. Neelapu, MD, Michael Dickinson, DMed Sci, Matthew L. Ulrickson, MD, Olalekan O. Oluwole, MBBS, MPH, Alex F. Herrera, MD, Catherine Thieblemont, MD PhD, Chaitra S. Ujjani, MD, Yi Lin, MD PhD, Peter A. Riedell, MD, Natasha Kekre, MD MPH, FRCPC, Sven de Vos, MD PhD, Yin Yang, MS, Francesca Milletti, PhD, Lovely Goyal, PhD, Jun Kawashima, MD, Julio C. Chavez, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-134449

Published: 2020

Journal Articles

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Julie M. Vose, MD MBA, Yi Lin, MD PhD, Lihua E Budde, MD PhD, David G. Maloney, MD PhD, Samantha Jaglowski, MD MPH, Peter A. Riedell, MD, Lazaros J. Lekakis, MD, Miguel-Angel Perales, MD, Jenny J. Kim, MD MS, Jun Kawashima, MD, Yin Yang, MS, John M. Rossi, MS, Lovely Goyal, PhD, Sattva S. Neelapu, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136136

Published: 2020

Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD

Blood (2019) 134 (Supplement_1): 4093.

https://doi.org/10.1182/blood-2019-126369

Published: 2019

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Demi Niforos, MS, Mark Kowalski, MD, PhD, Linda M Bavisotto, MD, Jun Kawashima, MD, Susie Jun, MD, PhD, Helen Collins, MD, Srinivasan Ramanathan, PhD

Blood (2013) 122 (21): 1590.

https://doi.org/10.1182/blood.V122.21.1590.1590

Published: 2013

Journal Articles

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Peter Lee, MD, PhD, Mark Kowalski, MD, PhD, Wei Deng, PhD, Demi Niforos, MS, Ayalew Tefferi, MD

Blood (2013) 122 (21): 108.

https://doi.org/10.1182/blood.V122.21.108.108

Published: 2013

Journal Articles

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Animesh Pardanani, MBBS, PhD, Jason Gotlib, Vikas Gupta, MD, FRCP, FRCPath, Andrew W. Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Linda M Bavisotto, MD, Jun Kawashima, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 178.

https://doi.org/10.1182/blood.V120.21.178.178

Published: 2012

NARROW

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only